| Study of factors influencing the decreased HDL associated PON1 activity with aging I Seres, G Paragh, E Deschene, T Fulop Jr, A Khalil Experimental gerontology 39 (1), 59-66, 2004 | 262 | 2004 |
| Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. G Kerekes, Z Szekanecz, H Dér, Z Sándor, G Lakos, L Muszbek, I Csipö, ... The Journal of rheumatology 35 (3), 398-406, 2008 | 251 | 2008 |
| Rheumatoid arthritis and metabolic syndrome G Kerekes, MT Nurmohamed, MA Gonzalez-Gay, I Seres, G Paragh, ... Nature Reviews Rheumatology 10 (11), 691-696, 2014 | 226 | 2014 |
| Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia G Paragh, P Balla, E Katona, I Seres, A Égerházi, I Degrell European archives of psychiatry and clinical neuroscience 252, 63-67, 2002 | 166 | 2002 |
| Assessment of subclinical vascular disease associated with ankylosing spondylitis N Bodnár, G Kerekes, I Seres, G Paragh, J Kappelmayer, ZG Némethné, ... The Journal of Rheumatology 38 (4), 723-729, 2011 | 142 | 2011 |
| Modulation of human lymphocyte proliferative response with aging N Douziech, I Seres, A Larbi, E Szikszay, PM Roy, M Arcand, G Dupuis, ... Experimental gerontology 37 (2-3), 369-387, 2002 | 141 | 2002 |
| The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia G Paragh, I Seres, Z Balogh, Z Varga, I Kárpáti, J Mátyus, L Újhelyi, ... Nephron 80 (2), 166-170, 1998 | 138 | 1998 |
| Serum paraoxonase activity changes in uremic and kidney-transplanted patients G Paragh, L Asztalos, I Seres, Z Balogh, L Löcsey, I Kárpáti, J Mátyus, ... Nephron 83 (2), 126-131, 1999 | 120 | 1999 |
| Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage M Harangi, I Seres, Z Varga, G Emri, Z Szilvássy, G Paragh, É Remenyik European Journal of Clinical Pharmacology 60, 685-691, 2004 | 111 | 2004 |
| Association of chemerin with oxidative stress, inflammation and classical adipokines in non‐diabetic obese patients P Fülöp, I Seres, H Lőrincz, M Harangi, S Somodi, G Paragh Journal of cellular and molecular medicine 18 (7), 1313-1320, 2014 | 85 | 2014 |
| Vitamin D insufficiency in a large MCTD population A Hajas, J Sandor, L Csathy, I Csipo, S Barath, G Paragh, I Seres, ... Autoimmunity reviews 10 (6), 317-324, 2011 | 81 | 2011 |
| Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus E Kiss, I Seres, T Tarr, Z Kocsis, G Szegedi, G Paragh Annals of the New York Academy of Sciences 1108 (1), 83-91, 2007 | 81 | 2007 |
| Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Z Balogh, I Seres, M Harangi, P Kovacs, GY Kakuk, GY Paragh Diabetes and Metabolism 27 (5; PART 1), 604-610, 2001 | 80 | 2001 |
| The effect of atorvastatin therapy on lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase A Kassai, L Illyés, HZ Mirdamadi, I Seres, T Kalmár, M Audikovszky, ... Clinical biochemistry 40 (1-2), 1-5, 2007 | 79 | 2007 |
| The human paraoxonase‐1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters HZ Mirdamadi, F Sztanek, Z Derdak, I Seres, M Harangi, G Paragh British journal of clinical pharmacology 66 (3), 366-374, 2008 | 74 | 2008 |
| Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels P Koncsos, I Seres, M Harangi, I Illyés, L Józsa, F Gönczi, L Bajnok, ... Pediatric research 67 (3), 309-313, 2010 | 70 | 2010 |
| The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease G Paragh, I Seres, M Harangi, Z Balogh, L Illyes, J Boda, Z Szilvássy, ... Diabetes & metabolism 29 (6), 613-618, 2003 | 70 | 2003 |
| Determination of DNA damage induced by oxidative stress in hyperlipidemic patients M Harangi, É Remenyik, I Seres, Z Varga, E Katona, G Paragh Mutation Research/Genetic Toxicology and Environmental Mutagenesis 513 (1-2 …, 2002 | 65 | 2002 |
| Structure prerequisite for antioxidant activity of silybin in different biochemical systems in vitro Z Varga, I Seres, E Nagy, L Ujhelyi, G Balla, J Balla, S Antus Phytomedicine 13 (1-2), 85-93, 2006 | 64 | 2006 |
| High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus K Gaál, T Tarr, H Lőrincz, V Borbás, I Seres, M Harangi, P Fülöp, ... Lipids in health and disease 15, 1-8, 2016 | 60 | 2016 |
Tósaki ÁrpádDebreceni Egyetem (University of Debrecen)E-mail megerősítve itt: pharm.unideb.hu
